丹参酮ⅡA磺酸钠联合依帕司他对糖尿病肾病患者肾功能和血流动力学指标的影响

Effects of TanshinoneⅡA Sodium Sulfonate Combined with Epalrestat on Renal Function and Hemodynamic Parameters in Patients with diabetes Nephropathy

目的 探讨糖尿病肾病患者实施丹参酮ⅡA磺酸钠联合依帕司他治疗对患者肾功能和血流动力学指标的影响。方法 选取本院2020年2月—2022年5月收治的88例糖尿病肾病患者,随机将其分为对照组和试验组,每组44例。对照组实施依帕司他治疗,试验组给予丹参酮ⅡA磺酸钠联合依帕司他治疗,治疗4周后,比较两组患者肾功能、血流动力学指标、临床疗效和不良反应情况。结果 治疗前,两组患者肾功能指标对比,差异无统计学意义(P>0.05);治疗后,试验组患者24h尿蛋白定量(1.03±0.32)g、BUN(7.62±0.57)mmol/L和Cre(71.24±10.17)μmol/L均高于对照组(P<0.05)。治疗前,两组患者血流动力学指标对比,差异无统计学意义(P>0.05);治疗后,试验组患者全血还原黏度(10.25±1.57)mPa·s、血黏度 (1.45±0.25)mPa·s和全血黏度(4.83±0.95)mPa·s均低于对照组(P<0.05)。试验组患者总有效率较95.45%明显高于对照组79.55%(P<0.05),两组患者不良反应发生率对比,差异无统计学意义(P>0.05)。结论 糖尿病肾病患者实施丹参酮ⅡA磺酸钠联合依帕司他治疗能够有效改善患者血流动力学,增强患者肾功能,临床疗效显著,安全性高。

Objective To investigate the effect of tanshinoneⅡA sulfonate sodium combined with epalrestat on renal function and hemodynamics in patients with diabetes nephropathy.Methods 88 patients with diabetes nephropathy admitted to our hospital from February 2020 to May 2022 were randomly divided into a control group and a test group,44 patients in each group.The patients in the control group were treated with epalrestat,and the patients in the test group were treated with sodium tanshinoneⅡA sulfonate combined with epalrestat.After 4 weeks of treatment,the renal function and hemodynamic indexes of the two groups were compared.Results Before treatment,there was no significant difference in renal function between the two groups(P>0.05).After treatment,24h urine protein quantification of patients in the test group was(1.03±0.32)g,BUN was(7.62±0.57)mmol/L and Cre was(71.24±10.17)μMol/L was higher than that in the control group(P<0.05).Before treatment,there was no significant difference in hemodynamic indexes between the two groups(P>0.05).After treatment,the whole blood reduced viscosity(10.25±1.57)mPa•s,blood viscosity(1.45±0.25)mPa•s and whole blood viscosity(4.83±0.95)mPa•s in the test group were lower than those in the control group(P<0.05).The total effective rate of patients in the test group was 95.45%,which was significantly higher than 79.55%in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion TanshinoneⅡA sodium sulfonate combined with epalrestat can effectively improve the hemodynamics and enhance the renal function of patients with diabetes nephropathy,with significant clinical efficacy and high safety.